← Back
Data updated: Mar 29, 2026
REGCON HOLDINGS
CardiovascularNeurologyGastroenterology
Generics
REGCON HOLDINGS is a generic drug manufacturer focused on Cardiovascular, Neurology, Gastroenterology.
1999
Since
41
Drugs
-
Trials
368
Approved (2yr)
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 38%
6 drugs
Neurology 25%
4 drugs
Gastroenterology 13%
2 drugs
Oncology 13%
2 drugs
Ophthalmology 13%
2 drugs
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
Active (25)
RIVAROXABAN LOFEXIDINE HYDROCHLORIDE BRIMONIDINE TARTRATE AND TIMOLOL MALEATE VARENICLINE TARTRATE ELETRIPTAN HYDROBROMIDE SUMATRIPTAN NEOSTIGMINE METHYLSULFATE MOXIFLOXACIN HYDROCHLORIDE RASAGILINE MESYLATE DORZOLAMIDE HYDROCHLORIDE DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE CETIRIZINE HYDROCHLORIDE CARVEDILOL BRIMONIDINE TARTRATE FLECAINIDE ACETATE FAMOTIDINE ENALAPRIL MALEATE SOTALOL HYDROCHLORIDE ACYCLOVIR NADOLOL ACETYLCYSTEINE BACLOFEN AMINOCAPROIC ACID SUCCINYLCHOLINE CHLORIDE THIOTEPA
Discontinued (13)
Company Info
- First Approval
- 1999-01-26
- Latest
- 2026-01-29
- Applications
- 46